GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Phase II Trial of GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Sponsor: Dana-Farber Cancer Institute
Terminated
participants are no longer being examined or receiving intervention
Other terminated trials from Dana-Farber Cancer Institute
Listed as NCT03765983, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by Dana-Farber Cancer Institute, it has been updated 15 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
▶ Show 10 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Jun 2024 [monthly]
Recruiting PHASE2
-
Feb 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Apr 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
May 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Mar 2019 — May 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
- Kazia Therapeutics Limited
For direct contact, visit the study record on ClinicalTrials.gov .